Autoimmune diseases and subsequent urological cancers - Abstract

PURPOSE: To examine the subsequent risk and prognosis of urological cancers among individuals diagnosed with autoimmune(AI) diseases.

MATERIALS AND METHODS: We analyzed systematically the risk and prognosis of prostate, kidney and bladder cancers among individuals diagnosed with any of 33 different AI diseases based on nation-wide Swedish database covering years 1964 through 2008. Standardized incidence ratios (SIRs) and hazard ratios (HRs) were calculated for subsequent urological cancers between 1964 and 2008 in individuals hospitalized for an AI disease.

RESULTS: Increased SIRs for urological cancers were recorded after 26 AI diseases; increased HRs for cancer-specific survival were noted after 4 AI diseases and for overall survival after 18 AI diseases. The highest SIRs were seen for kidney cancer after polyarteritis nodosa (2.85), and polymyositis/dermatomyositis (2.68), and for bladder cancer after polymyositis/dermatomyositis (2.45). For prostate cancer, the highest risk (1.70) was observed after polyarteritis nodosa; the SIRs were lower in follow-up period 1990 to 2008 compared to the previous period. Individuals diagnosed with prostate and kidney cancers showed an improved cancer-specific prognosis, in contrast to the poorer overall prognosis for all 3 urological cancers.

CONCLUSIONS: The risks for urological cancers were increased after all AI diseases and most significant changes after individual AI diseases were towards higher risks. The data on survival were reassuring that AI diseases influenced the prognosis of cancer-specific mortality marginally. However, the overall survival was decreased for the three cancers.

Written by:
Liu X, Ji J, Forsti A, Sundquist K, Sundquist J, Hemminki K.   Are you the author?
Center for Primary Health Care Research, Lund University, Malmö, Sweden; College of Lab Medicine, Hebei North University, 075800 Zhangjiakou, China.

Reference: J Urol. 2012 Dec 7. pii: S0022-5347(12)05838-7.
doi: 10.1016/j.juro.2012.12.014

PubMed Abstract
PMID: 23228387 Prostate Cancer Section